← Back to headlines
HSE Drugs Group Recommends Against Covering Friedreich’s Ataxia Drug Cost
The HSE Drugs Group has recommended against covering the cost of a drug for Friedreich’s ataxia, citing challenges in balancing the drug's effectiveness against its high cost.
12 Aug, 10:59 — 12 Aug, 10:59
